BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 33820756)

  • 21. Results of surveillance in individuals at high-risk of pancreatic cancer: A systematic review and meta-analysis.
    Signoretti M; Bruno MJ; Zerboni G; Poley JW; Delle Fave G; Capurso G
    United European Gastroenterol J; 2018 May; 6(4):489-499. PubMed ID: 29881603
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pancreatic Cancer Surveillance and Novel Strategies for Screening.
    Dudley B; Brand RE
    Gastrointest Endosc Clin N Am; 2022 Jan; 32(1):13-25. PubMed ID: 34798981
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in
    Saldia A; Olson SH; Nunes P; Liang X; Samson ML; Salo-Mullen E; Marcell V; Stadler ZK; Allen PJ; Offit K; Kurtz RC
    Cancer Prev Res (Phila); 2019 Sep; 12(9):599-608. PubMed ID: 31337648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Results of First-Round of Surveillance in Individuals at High-Risk of Pancreatic Cancer from the AISP (Italian Association for the Study of the Pancreas) Registry.
    Paiella S; Capurso G; Cavestro GM; Butturini G; Pezzilli R; Salvia R; Signoretti M; Crippa S; Carrara S; Frigerio I; Bassi C; Falconi M; Iannicelli E; Giardino A; Mannucci A; Laghi A; Laghi L; Frulloni L; Zerbi A
    Am J Gastroenterol; 2019 Apr; 114(4):665-670. PubMed ID: 30538291
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening and Surveillance for Pancreatic Adenocarcinoma in High-Risk Individuals.
    Labiner AJ; Aronson A; Lucas AL
    Hematol Oncol Clin North Am; 2022 Oct; 36(5):929-942. PubMed ID: 36265991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer.
    Lorenzo D; Rebours V; Maire F; Palazzo M; Gonzalez JM; Vullierme MP; Aubert A; Hammel P; Lévy P; de Mestier L
    World J Gastroenterol; 2019 Sep; 25(34):5082-5096. PubMed ID: 31558858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals.
    Levink IJM; Klatte DCF; Hanna-Sawires RG; Vreeker GCM; Ibrahim IS; van der Burgt YEM; Overbeek KA; Koopmann BDM; Cahen DL; Fuhler GM; Wuhrer M; Bonsing BA; Tollenaar RAEM; Vleggaar FP; Vasen HFA; van Leerdam ME; Bruno MJ; Mesker WE
    Pancreatology; 2022 May; 22(4):497-506. PubMed ID: 35414481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival.
    Dbouk M; Katona BW; Brand RE; Chak A; Syngal S; Farrell JJ; Kastrinos F; Stoffel EM; Blackford AL; Rustgi AK; Dudley B; Lee LS; Chhoda A; Kwon R; Ginsberg GG; Klein AP; Kamel I; Hruban RH; He J; Shin EJ; Lennon AM; Canto MI; Goggins M
    J Clin Oncol; 2022 Oct; 40(28):3257-3266. PubMed ID: 35704792
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Value of endoscopic ultrasound-guided fine needle aspiration in pretest prediction and diagnosis of pancreatic ductal adenocarcinoma].
    Wu L; Guo W; Li Y; Cheng T; Yao Y; Zhang Y; Liu B; Zhong M; Li S; Deng X; Zhu W
    Nan Fang Yi Ke Da Xue Xue Bao; 2018 Sep; 38(10):1171-1178. PubMed ID: 30377133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium.
    Goggins M; Overbeek KA; Brand R; Syngal S; Del Chiaro M; Bartsch DK; Bassi C; Carrato A; Farrell J; Fishman EK; Fockens P; Gress TM; van Hooft JE; Hruban RH; Kastrinos F; Klein A; Lennon AM; Lucas A; Park W; Rustgi A; Simeone D; Stoffel E; Vasen HFA; Cahen DL; Canto MI; Bruno M;
    Gut; 2020 Jan; 69(1):7-17. PubMed ID: 31672839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Pancreatic cancer-screening or surveillance?].
    Sirtl S; Vornhülz M; Hofmann FO; Mayerle J; Beyer G
    Radiologie (Heidelb); 2023 Dec; 63(12):908-915. PubMed ID: 37878016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cohort profile and heritability assessment of familial pancreatic cancer: a nation-wide study.
    Tan M; Brusgaard K; Gerdes AM; Mortensen MB; Detlefsen S; Schaffalitzky de Muckadell OB; Joergensen MT
    Scand J Gastroenterol; 2021 Aug; 56(8):965-971. PubMed ID: 34165379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance.
    Konings IC; Harinck F; Kuenen MA; Sidharta GN; Kieffer JM; Aalfs CM; Poley JW; Smets EM; Wagner A; van Rens A; Vleggaar FP; Ausems MG; Fockens P; van Hooft JE; Bruno MJ; Bleiker EM;
    Fam Cancer; 2017 Jan; 16(1):143-151. PubMed ID: 27629874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification and Validation of a Biomarker Signature in Patients With Resectable Pancreatic Cancer via Genome-Wide Screening for Functional Genetic Variants.
    Dimitrakopoulos C; Vrugt B; Flury R; Schraml P; Knippschild U; Wild P; Hoerstrup S; Henne-Bruns D; Wuerl P; Graf R; Breitenstein S; Bond G; Beerenwinkel N; Grochola LF
    JAMA Surg; 2019 Jun; 154(6):e190484. PubMed ID: 30942874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance.
    Katona BW; Klute K; Brand RE; Everett JN; Farrell JJ; Hawthorne K; Kaul V; Kupfer SS; Paiella S; Simeone DM; Sussman DA; Zogopoulos G; Lucas AL; Kastrinos F;
    Cancer Prev Res (Phila); 2023 Jun; 16(6):343-352. PubMed ID: 37259800
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study.
    Canto MI; Goggins M; Hruban RH; Petersen GM; Giardiello FM; Yeo C; Fishman EK; Brune K; Axilbund J; Griffin C; Ali S; Richman J; Jagannath S; Kantsevoy SV; Kalloo AN
    Clin Gastroenterol Hepatol; 2006 Jun; 4(6):766-81; quiz 665. PubMed ID: 16682259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiating Mass-Forming Autoimmune Pancreatitis From Pancreatic Ductal Adenocarcinoma on the Basis of Contrast-Enhanced MRI and DWI Findings.
    Choi SY; Kim SH; Kang TW; Song KD; Park HJ; Choi YH
    AJR Am J Roentgenol; 2016 Feb; 206(2):291-300. PubMed ID: 26797355
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dilemmas in the management of screen-detected lesions in patients at high risk for pancreatic cancer.
    Ibrahim IS; Bonsing BA; Swijnenburg RJ; Welling L; Veenendaal RA; Wasser MN; Morreau H; Inderson A; Vasen HF
    Fam Cancer; 2017 Jan; 16(1):111-115. PubMed ID: 27406244
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A review of lifestyle, metabolic risk factors, and blood-based biomarkers for early diagnosis of pancreatic ductal adenocarcinoma.
    Pang Y; Holmes MV; Chen Z; Kartsonaki C
    J Gastroenterol Hepatol; 2019 Feb; 34(2):330-345. PubMed ID: 30550622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance of high-risk individuals for pancreatic cancer with EUS and MRI: A meta-analysis.
    Kogekar N; Diaz KE; Weinberg AD; Lucas AL
    Pancreatology; 2020 Dec; 20(8):1739-1746. PubMed ID: 33077384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.